Generic Name |
Imatinib + BYL719 | |
---|---|---|
IND |
||
Brand Name (US) |
||
Manufacturer |
Novartis | |
Drug Type |
||
Delivery |
Oral | |
Approval Status |
||
Indications |
||
Overall Strategy |
KIT Protein Based + Oncogenic Signal Path Based | |
Strategy |
Block KIT + Block KIT Signal Path | |
Drug Category |
KIT/PDGFRA inhibitor + PI3K inhibitor |
Links |
|
Trials of this drug |
|
|
A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients |
Trial results |
|
Novartis Clinical Trial Results Website | |